Agree. Anything the government touches merely crawls forward... However, this doesn't mean saavy institutional level investors or big pharma isnt already looking to position here. The CEO interview essentially discusses "open pursestrings" while waiting for the tier 3 NIH studies to complete. Not sure how much more pre-IND success is needed for those entities to jump aboard in some fashion...
Having 2 other promising drug platforms progressing is beneficial as well. IMO.